<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642395</url>
  </required_header>
  <id_info>
    <org_study_id>0603603</org_study_id>
    <nct_id>NCT00642395</nct_id>
  </id_info>
  <brief_title>Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)</brief_title>
  <official_title>Velcade®-Melphalan Association as Conditioning Regimen Before Autologous Stem-cell Transplantation in Multiple Myeloma Patients Under 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intergroupe Francophone du Myelome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensification with autologous stem cell (ASCT) is currently the most effective treatment
      for subjects under 65 and the essential goal is to achieve complete response (CR) or very
      good partial response (VGPR= greater than 90% reduction of monoclonal component). However,
      only 50% of patients achieve this CR/VGPR even with tandem ASCT early in the course of
      disease.

      Optimization of the conditioning regimen could improve this CR/VGPR rate. The combinaison of
      Velcade and HD Melphalan has never been evaluated. However, at conventional doses, Velcade
      potentiates the antimyeloma effect of Melphalan without inducing any common toxicity.

      This study will be conducted in patients under the age of 65 with de novo multiple myeloma or
      in first relapse, with Salmon and Durie stage of III, II, I with one symptomatic bone lesion
      (radiological)and no contraindication to intensification. The primary objective will be to
      increase the CR/VGPR rate 3 months after autologous peripheral blood stem cell
      transplantation conditioned by Velcade-Melphalan from 40% to 70%. With alpha=5% and bêta=10%,
      61 patients will be included.

      Secondary objectives will be to assess the toxicity of the Velcade-Melphalan conditioning
      regimen, the progression-free survival and the overall survival after intensification.
      Response rates will be evaluated according to the response criteria defined by. Analysis will
      be performed on an intention-to-treat basis.

      After conventional induction therapy and PBSC collection, patients will be offered this new
      conditioning regimen. they will be free to refuse this regimen, in which case they will
      receive standard intensification therapy by Melphalan 200 mg/m² followed by autologous stem
      cell transplantation.

      Evaluation will occur at 3 months post intensification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Complete Response and Very Good Partial Response (VGPR) rates 3 months after autologous blood stem cell transplantation conditioned by Velcade-Melphalan</measure>
    <time_frame>3 months after autologous stem cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the toxicity of this Velcade-Melphalan conditioning regimen (hematological and visceral toxicity-NCI criteria) - To assess the progression-free survival after transplantation - To assess the overall survival after tran</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bortézomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>bortezomib-Melphalan</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At time of diagnosis

          -  De novo multiple myeloma patients under 65 or in first relapse, in whom screening for
             chromosome 13 deletion and beta2microglobulin assay have been performed.

          -  Salmon and Durie Stage: III, II, I with symptomatic bone lesion (radiological)

          -  Patient's written informed consent

          -  No clinical signs of heart failure or coronary insufficiency with LVEF&gt;50%

          -  No hepatic in insufficiency: bilirubin&lt;35μmol/l and SGOT, SGPT, alkaline phosphatase
             less than 2.5 N

          -  No respiratory insufficiency: normal pulmonary function tests and DLCO&gt;50%

          -  No pre-existing renal impairment not related to the disease

          -  No history of any other malignant disease with the exception of basal cell carcinoma
             and stage I cervical cancer

          -  Negative HIV serology

          -  Effective contraception when justified

        At the time of transplantation

          -  Good performance status (WHO score≤2)

          -  Creatinine≤170μmol/l and no ineligibility criteria for intensification

          -  Stem cells harvest ≥ 5x10E6 CD34/kg for 2 ASCT

          -  Absence of progressive disease before transplantation

        Exclusion Criteria:

          -  Known refusal of the subject to participate to the study

          -  Female subject who is pregnant or breast-feeding

          -  History of allergy to any of the study medications, their analogues, or excipients in
             the various formulations

          -  Main liver insufficiency

          -  ≥ Grade 3 peripheral neuropathy on clinical examination within 14 days before
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murielle ROUSSEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Purpan Hospital - UH Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service of Blood Deseases - South Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Bocage Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Cote Basque Hospital</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Minjoz Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - A. Morvan Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - F. Baclesse Center</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Army Instruction Hospital of Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - UH of Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Oncohematology - Louis Pasteur Hospital</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Bocage Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - General Hospital</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - A. Michallon Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Claude Hurriez Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Léon Bérard Center</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Lyon Sud Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Paoli Calmette Institute</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Notre Dame du Bon Secours Hospital</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Blood Deseases - UH of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Archet 1 Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Oncology - Archet 1 Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Blood Deseases - Saint Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Jean Bernard Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - R.Debré Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology -Henri Becquerel Center</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Hautepierre Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Clinical Hematology - Purpan hospital TSA 40031</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Onco-Hematology - Bretonneau Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology - Brabois Hospital</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Hematology -Gustave Roussy Institute</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pégourié B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M; Intergroupe Francophone du Myélome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010 Jan 7;115(1):32-7. doi: 10.1182/blood-2009-06-229658. Epub 2009 Nov 2.</citation>
    <PMID>19884643</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Autologous Stem Cells Transplantation</keyword>
  <keyword>High Dose Melphalan</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

